Jeremiah Johnson, executive director of PrEP4All, a company dedicated to HIV prevention and treatment, talks about the significance of preexposure anaphylaxis and why he’s hesitant to leap over the Lenacapavir breakthrough bandwagon. The neatest thing about RTP is the fact